NCT01864538 2025-05-11
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ImmunoGenesis
Phase 2 Terminated
ImmunoGenesis
Grupo Espanol de Tumores Neuroendocrinos
The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio
Merck KGaA, Darmstadt, Germany